Researchers can now order their mutation of choice in bit.bio’s opti-ox TM powered human-iPSC derived cells, receiving consistent, defined, cryopreserved products that can be immediately incorporated ...

OpenAI is bragging that its forthcoming models are so advanced, they may be capable of building brand-new bioweapons. In a recent blog post, the company said that even as it builds more and more ...

Immorta Bio Inc. has reported new data demonstrating that its combination therapy of Senovax, a first-in-class senolytic immunotherapy, and personalized mesenchymal stem cells (pMSCs) from its ...

The PharmTech Group spoke with BIOVECTRA's director of Business Development, Nucleic Acid Modalities, Jessica Madigan, about the concept of flexibility in outsourcing and the 2024 BIO Convention.

BioTechniques Digital Editor, Tristan Free, catches up with Guohao Dai, Associate Professor of Bioengineering at Northeastern University (MA, USA), to discuss his recent work making improvements in ...

Accurate cancer models are integral to the success of preclinical research yet have proven elusive. Mindy Goldsborough (ATCC, VA, USA) discusses the ongoing efforts to develop improved in vitro models ...